Assenagon Asset Management
REGN icon

Assenagon Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Assenagon Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$153M Buy
244,927
+37,139
+18% +$25.3M 0.19% 99
2026
Q1 		$161M Sell
207,788
-25,443
-11% -$19.5M 0.24% 70
2025
Q4 		$180M Sell
233,231
-244,579
-51% -$166M 0.25% 67
2025
Q3 		$269M Buy
477,810
+54,485
+13% +$30.8M 0.37% 50
2025
Q2 		$222M Sell
423,325
-58,064
-12% -$32.4M 0.33% 66
2025
Q1 		$305M Buy
481,389
+303,785
+171% +$209M 0.51% 30
2024
Q4 		$127M Buy
177,604
+4,745
+3% +$3.98M 0.2% 92
2024
Q3 		$182M Buy
172,859
+44,457
+35% +$49.5M 0.33% 55
2024
Q2 		$135M Sell
128,402
-61,283
-32% -$59.4M 0.3% 66
2024
Q1 		$183M Sell
189,685
-26,838
-12% -$25.5M 0.43% 43
2023
Q4 		$190M Buy
216,523
+122,103
+129% +$101M 0.5% 31
2023
Q3 		$77.7M Sell
94,420
-23,865
-20% -$18.8M 0.24% 70
2023
Q2 		$85M Sell
118,285
-84,982
-42% -$65.5M 0.29% 57
2023
Q1 		$167M Buy
203,267
+81,231
+67% +$61.3M 0.59% 34
2022
Q4 		$88M Buy
122,036
+39,065
+47% +$28.8M 0.32% 68
2022
Q3 		$57.2M Buy
82,971
+12,715
+18% +$8M 0.22% 96
2022
Q2 		$41.5M Buy
70,256
+4,735
+7% +$3.08M 0.15% 123
2022
Q1 		$45.8M Buy
65,521
+35,303
+117% +$22.3M 0.13% 138
2021
Q4 		$19.1M Sell
30,218
-10,179
-25% -$6.26M 0.06% 218
2021
Q3 		$24.4M Buy
40,397
+31,315
+345% +$19.4M 0.08% 188
2021
Q2 		$5.07M Sell
9,082
-182,599
-95% -$92.5M 0.02% 483
2021
Q1 		$90.7M Buy
191,681
+35,429
+23% +$17.2M 0.37% 47
2020
Q4 		$75.5M Buy
+156,252
New +$84.3M 0.33% 63
2020
Q3 		– Sell
-34,668
Closed -$21.6M – 1315
2020
Q2 		$21.6M Buy
34,668
+33,409
+2,654% +$19M 0.14% 101
2020
Q1 		$615K Sell
1,259
-27,029
-96% -$11.1M ﹤0.01% 612
2019
Q4 		$10.6M Sell
28,288
-5,878
-17% -$1.98M 0.07% 181
2019
Q3 		$9.48M Sell
34,166
-67,419
-66% -$20M 0.06% 181
2019
Q2 		$31.8M Buy
101,585
+3,768
+4% +$1.25M 0.24% 76
2019
Q1 		$40.2M Buy
97,817
+62,022
+173% +$25.5M 0.38% 59
2018
Q4 		$13.4M Sell
35,795
-74,776
-68% -$27.4M 0.15% 112
2018
Q3 		$44.7M Sell
110,571
-3,330
-3% -$1.27M 0.44% 52
2018
Q2 		$39.3M Buy
113,901
+68,562
+151% +$21.4M 0.45% 59
2018
Q1 		$15.6M Buy
45,339
+6,880
+18% +$2.39M 0.2% 121
2017
Q4 		$14.5M Sell
38,459
-83,515
-68% -$33.8M 0.15% 136
2017
Q3 		$54.5M Buy
+121,974
New +$58M 0.51% 54
2017
Q2 		– Sell
-760
Closed -$295K – 278
2017
Q1 		$295K Buy
+760
New +$282K 0.01% 238

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
HCM
Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return
LI
LMCG Investments Boston, Massachusetts $1.87B AUM 50.61% 1-Year Est. Return

Assenagon Asset Management's REGN Position: Q2 2026 in Review

Assenagon Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 18% in Q2 2026, buying an estimated $25.3M and bringing the position to 244,927 shares worth $153M. The position accounts for 0.19% of the portfolio, ranked #99.

Assenagon Asset Management first reported a position in REGN in Q1 2017 and has held it in 36 quarters since. The position peaked at $305M in Q1 2025. 262 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Assenagon Asset Management held 244,927 shares of Regeneron Pharmaceuticals worth $153M as of Q2 2026.
  • Assenagon Asset Management bought 37,139 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $25.3M.
  • Regeneron Pharmaceuticals made up 0.19% of Assenagon Asset Management's portfolio in Q2 2026, its #99 holding.
  • Assenagon Asset Management first reported a position in Regeneron Pharmaceuticals in Q1 2017 and has held it in 36 quarters since.
  • Assenagon Asset Management's Regeneron Pharmaceuticals position peaked at $305M in Q1 2025.
  • 262 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.